Does Rapid Transition to Insulin Therapy in Subjects with Newly Diagnosed Type 2 Diabetes Mellitus Benefit Glycaemic Control and Diabetes-related Complications? A German Population-based Study

Abstract

Objective: The aim of this study was to assess whether earlier transition to insulin in subjects with newly diagnosed type 2 diabetes improves glycaemic control and reduces diabetes-related complications. Methods: Subjects with newly diagnosed type 2 diabetes, and 2 or more recorded glycosylated haemoglobin (HbA1c) values, were identified from the Mediplus Germany database between June 1993 and May 2001. Subjects were stratified by treatment group: diet and exercise, sulfonylurea drugs, antihyperglycaemic drugs, insulin, or insulin plus sulfonylurea or antihyperglycaemic drugs. Treatment modifications were tracked over time and a rapid transition to insulin recorded if insulin was the initial therapy administered or the immediate treatment after diet and exercise. The area under the curve (AUC) for HbA1c was calculated and a linear regression model used to explain AUC as a function of rapid transitioning to insulin. A Cox proportional hazard model assessed the relationship between the time to first complication and AUC, rapid transition to insulin, and the number of treatment modifications. Results: Of the 3136 subjects who met the study entry criteria, just 151 (4.8%) were initiated on insulin; after 5 years only 811 (25.9%) subjects had received insulin therapy. In the regression model explaining AUC, rapid transition to insulin significantly improved glycaemic control (-0.20, p=0.03). The Cox proportional hazard model demonstrated that the time to first complication was negatively related to AUC (-0.05, p<0.01) and the rapid use of insulin (-0.27, p<0.01), and positively related to the number of treatment modifications (0.07, p<0.01). Conclusions: Using actual real world clinical practice data, the present study found that the immediate use of insulin in patients with type 2 diabetes improved blood glucose control as measured by the AUC for HbA1c readings. This, in turn, reduced the risk of diabetes-related complications. In contrast, we observed that a stepwise transition treatment pattern (switching from diet and exercise to sulfonylureas and then perhaps to antihyperglycaemic agents and finally insulin) increased the risk of diabetes-related complications. Greater effort is required to remove some of the barriers currently preventing earlier initiation of insulin therapy in patients with type 2 diabetes.

Key words

Type 2 diabetes mellitus - insulin therapy - HbA1c - diabetes-related complications - diabetes diagnosis

References

• 1 Campbell R, White J, Jr. Insulin therapy in type 2 diabetes.  J Am Pharm Assoc. 2002;  42 602-611
• 2 Dietlin G, Schroder-Bernhardi D. Use of the mediplus patient database in healthcare research.  Int J Clin Pharmacol Ther. 2002;  40 130-133
• 3 The Diabetes Control Complications Trial Research Group . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.  N Engl J Med. 1993;  329 977-986
• 4 Duggan AK. Modeling different approaches to the management of upper gastrointestinal disease.  Pharmacoeconomics. 1998;  14 ((Suppl 2)) 25-37
• 5 Eggleston A. Cost effectiveness of treatment for gastro-esophageal reflux disease in clinical practice: a clinical database analysis.  Gut. 1998;  42 13-16
• 6 Freemantle N, Blonde L, Duhot D, Hompesch M, Eggertsen R, Hobbs FDR, Martinez L, Ross S, Bolinder B, Stridde E. Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes.  Diabetes Care. 2005;  28 427-428
• 7 Hasford J, Mimran A, Simons WR. A population-based European cohort study of persistence in newly diagnosed hypertensive patients.  J Hum Hypertens. 2002;  16 569-575
• 8 Hughes D, McGuire A. The direct costs to the NHS of discontinuing and switching prescriptions for hypertension.  J Hum Hypertens. 1998;  12 533-537
• 9 Jones JK, Gorkin L, Lian JF, Staffa JA, Fletcher AP. Discontinuation of, and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population.  Br Med J. 1995;  311 293-295
• 10 Kennedy L. Emerging treatments-glycemic control and beyond. In: Mazzaferri EL (ed.). Yearbook of Endocrinology. pp13-16 Elsevier, Philadelphia 2005
• 11 Korytkowski M. When oral agents fail: practical barriers to starting insulin.  Int J Obes Relat Metab Disord. 2002;  26 ((Suppl 3)) S18-S24
• 12 Krobot KJ, Steinberg HW, Pfaffenrath V. Migraine prescription density and recommendations.  Results of the PCAOM study. Cephalalgia. 1999;  19 511-519
• 13 Lawrenson R. Patterns of antidepressant prescription in general practice: lessons from the MediPlus database.  Primary Care Psychiatry. 1999;  5 3-7
• 14 Morris A. The reality of type 2 diabetes treatment today.  Int J Clin Pract Suppl. 2001;  121 32-35
• 15 Rathmann W, Haastert B, Roseman JM, Giani G. Cardiovascular drug prescriptions and risk of depression in diabetic patients.  J Clin Epidemiol. 1999;  52 1103-1109
• 16 Simons WR, Kemp R, Bolinder B. A five year longitudinal analysis of the health benefits of transitioning toward insulin therapy sooner in newly diagnosed type II diabetics.  Value Health 3. 2000;  , [no. 5]:DB3 (Abstract)
• 17 Stratton IM, Adler AI, Neil AW, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 25): prospective observational study.  BMJ. 2000;  321 405-412
• 18 Todd J. Venous thromboembolic disease and combined oral contraceptives: a re-analysis of the MediPlus database.  Hum Reprod. 1999;  14 1500-1505
• 19 UK Prospective Diabetes Study (UKPDS) Group . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).  Lancet. 1998;  352 837-853
• 20 Weyer C, Borgardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes.  J Clin Invest. 1999;  104 787-794

Correspondence